GlobalData, a data and analytics company, has reported that further development of chimeric antigen receptor (CAR)-T cell therapies in solid tumours will require collaboration with industry.
According to poll results from Pew Research Center, the American public is accepting of gene editing in animals that could benefit human health, potentially removing a barrier to research, as noted by a pharma analyst at GlobalData.
Here, Trevor Marshall, director of global engineering at Zenith Technologies, goes into detail about how integrating and automating cell therapy production with MES will help grow the personalised medicine sector and ultimately benefit patients
Here, Tony Hitchcock, technical director at Cobra Biologics and Joanne Anderson, business development director at Symbiosis, discuss the challenges associated with manufacturing for gene therapies.
GlobalData has stated that according to its latest research immune-based gene therapy candidates should prevail in oncology, however, this novel approach is unchartered territory in oncology and will require new regulatory guidelines
In this article, Frances Salisbury (partner) and Adam Gregory (associate) — European Patent Attorneys in the Life Sciences team at Mewburn Ellis — discuss innovation and IP of CAR-T therapies in more detail.
Edison Investment Research, has released an independent and detailed analyst report into T-cell cancer therapies, highlighting the potential and limitations of current CAR-T approaches for most tumour types.
The Sartorius and Science Prize for Regenerative Medicine & Cell Therapy is focused towards scientists advancing research within the relevant fields, with the winner receiving $25,000 in prize money and being published in Science magazine
The BIOCAPAN Project has been funded for four years by the European Commission. It was started to develop an innovative GMP-grade cell-therapy product to treat diabetes without insulin injections, says Florence Rivera
